公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2008 | Carbonic Anhydrase Iii Promotes Transformation and Invasion Capability in Hepatoma Cells through Fak Signaling Pathway | HONG, CHIH-CHEN; LIANG, SAN-CHI; YAN, MING-DE; LAI, GI-MING; CHENG, ANN-LII; CHUANG, SHUANG-EN; 鄭安理 | Molecular Carcinogenesis | 38 | 35 | |
1989 | Characterization and Spectrum of Post-Thymic T Cell Malignancies in Taiwan | Su, I. J.; Cheng, Ann-Lii; Chen, Yee-Chun; Wang, C. H.; 鄭安理 | Cancer | | | |
1988 | Characterization of the spectrum of postthymic T-cell malignancies in Taiwan | Su, Ih-Jen; Wang, Chiu-Hwa; Cheng, Ann-Lii; Chen, Yao-Chang; Hsieh, Hong-Jong; Tien, Hwei-Fang; Tsai, Woei; Hu, Chung-Yi; Chen, Pei-Jer; Chen, Jen-Yang; Su, Hwei-Chi; Chuang, Sou-Ming; Shen, Ming-Ching; Kardin, Ma | Cancer,61() | | | |
1990 | Chemotherapy of Breast Cancer | CHENG, ANN-LII; CHEN, YAO-CHANG; 鄭安理; 陳耀昌 | 醫學繼續教育,v.2 | | | |
1993 | Chronic Oral VP-16 and Tamoxifen in the Treatment of Far-Advanced Hepatocellular Carcinoma | Cheng, Ann-Lii; Chen, Yee-Chun; 鄭安理 | Proceedings:Annual Meeting of the American Society of Clinical Oncology | | | |
2015 | Clinical significance of LKB1 protein and gene expression in breast cancer. | Chen, I. Chun; Chang, Yuan-Ching; Lu, Yen-Shen; Huang, Chiun-Sheng; Kuo, Wen-Hung; Wang, Ming-Yang; Kuo, Kuan-Ting; Wu, Pei-Fang; Hsueh, Tsu-Hsin; Lin, Ching-Hung; Cheng, Ann-Lii; 鄭安理 | J. Clin. Oncol. | | | |
2013 | Comparison of afatinib and erlotinib as radiosensitizing agents in bladder cancer cells | Tsai, Yu-Chieh; Tuan, Tsung-Fan; Ho, Pei-Yin; Liu, Wei-Lin; Chang, Liang-Yu; Pu, Yeong-Shiau; Cheng, Ann-Lii; Chen, Jason Chia-Hsien; 鄭安理; 成佳憲 | Cancer Res. | 0 | 0 | |
1992 | Cutaneous Angiocentric T Cell Lymphoma Associated with Epstein-Barr Virus | Cheng, Ann-Lii; Hsieh, H. C.; Tien, Hwei-Fang; Tsai, T. F.; Su, I. J.; Lu, Y. C.; 鄭安理 | Journal of American Academy Dermatology | | | |
1994 | Cutaneous Manifestations of Epstein-Barr Virus-Associated T-Cell Lymphoma | Cheng, Ann-Lii; Su, I. J.; Tsai, T. F.; 鄭安理 | Journal of American Academy Dermatology | | | |
1991 | Cutaneous Manifestations of Peripheral T-Cell Lymphoma | Su, I. J.; Hsieh, H. C.; Cheng, Ann-Lii; 鄭安理 | Journal of American Academy Dermatology | | | |
1990 | Cutaneous Manifestations of Postthymic T Cell Malignancies:Description of Five Clinicopathologic Subtypes | 蘇益仁; 吳英俊; 陳耀昌; Hsieh, Hong-Chung; 鄭安理; 王秋華; Kadin Marshall E; Su, Ih-Jen; Wu, Ying-Chin; Chen, Yao-Chang; Cheng, Ann-Lii; Wang, Chiu-Hwa | Journal of the American Academy of Dermatology | | | |
2014 | Development of GADD45 beta (growth arrest DNA damage-inducible gene 45 beta) agonists for the treatment of hepatocellular carcinoma (HCC) | Hsu, Chiun; Ou, Da-Liang; Chen, Kuen-Feng; Lin, Zhong-Zhe; Cheng, Ann-Lii; Shiau, Chung-Wai; 鄭安理 | Cancer Res. | 0 | 0 | |
1991 | Different Tumor Biology between Peripheral T-Cell Lymphoma and Diffuse B-Cell Lymphoma-Implication on Treatment Planning | Cheng, Ann-Lii; Su, I. J.; 鄭安理 | Program and Abstract, Fourth International Conference on Malignant Lymphoma | | | |
1990 | Differential Responses to Chemotherapy in Peripheral T-Cell Lymphoma and Diffuse B-Cell Lymphoma-Features Useful in Treatment Planning | Cheng, Ann-Lii; Wang, C. H.; Chen, Yee-Chun; 鄭安理 | Journal of Chinese Oncology Society, ROC | | | |
1994 | Differential Susceptibility to Cytotoxic and Biologic Agents of Lymphoma Cell Lines | Cheng, Ann-Lii; Su, I. J.; 鄭安理 | Annual Meeting of the American Association for Cancer Research. Proceedings | | | |
1993 | Disruption of Cellular Energy Balance by Suramin in Intact Human Prostatic Carcinoma Cells, a Likely Antiproliferative Mechanism | Rago, R.; Mitchen, J.; Cheng, Ann-Lii; 鄭安理 | Cancer Research | | | |
2009 | Effect of Macroscopic Vascular Invasion (Mvi), Extrahepatic Spread (Ehs), and Ecog Performance Status (Ecog Ps) on Outcome in Patients with Advanced Hepatocellular Carcinoma (Hcc) Treated with Sorafenib: Analysis of Two Phase Iii, Randomized, Double-Blind | CHENG, ANN-LII; TSAO, CHAO-JUNG; 鄭安理 | JOURNAL OF CLINICAL ONCOLOGY | | | |
2015 | Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials. | Meyer, Tim; Palmer, Daniel H.; Chao, Yee; Choi, Caren; Deptala, Andrzej; Fartoux, Laetitia; Feng, Yin-Hsun; Graham, Janet Shirley; Hocke, Julia; Kim, Tae-You; Lin, Deng-Yn; Ma, Yuk Ting; Peck-Radosavljevic, Markus; Ross, Paul J.; Ryoo, Baek-Yeol; Wenz, Arne; Yen, Chia-Jui; Loembe, Arsene-Bienvenu; Cheng, Ann-Lii | J. Clin. Oncol. | | | |
2015 | Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials. | Meyer, Tim; Palmer, Daniel H.; Chao, Yee; Choi, Caren; Deptala, Andrzej; Fartoux, Laetitia; Feng, Yin-Hsun; Graham, Janet Shirley; Hocke, Julia; Kim, Tae-You; Lin, Deng-Yn; Ma, Yuk Ting; Peck-Radosavljevic, Markus; Ross, Paul J.; Ryoo, Baek-Yeol; Wenz, Arne; Yen, Chia-Jui; Loembe, Arsene-Bienvenu; Cheng, Ann-Lii; 鄭安理 | J. Clin. Oncol. | | | |
2009 | Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma (Hcc): Asia-Pacific (Ap) Trial Subgroup Analyses by Baseline Transaminase (Alt/Ast)/(Alpha)-Fetoprotein (Afp) Levels | TSAO, CHAO-JUNG; CHENG, ANN-LII; 鄭安理 | JOURNAL OF CLINICAL ONCOLOGY | | | |